Biogen’s diversification decision, TIGIT preview & China Summit wrap

With Al Sandrock retiring at year-end, Biogen may be at a decision point: diversify its pipeline beyond neurology or stay the course. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the challenges Biogen faces — slumping sales, a slow Aduhelm launch and the heightened biology risk that comes with a neurology-focused pipeline — and how the biotech’s new head of R&D could go about diversifying into areas such as immunology. ...